Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification

Cornet, Edouard; Mossafa, Hossein; Courel, Karine; Lesesve, Jean-François; Troussard, Xavier

doi:10.1186/s13104-015-1742-3

BMC Research Notes

Table 5 Recurrent Copy Number Aberrations (CNA) in CD19⁺ B-cells. 143 CNA had been observed

From: Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification

Chr	Cytoregion	Recurrence	Recurrence including mosaicism	CN state	Gene	Minimal common size (kbp)	Genic region: total (T) Exonic (E) Intronic (I)	CNA reported in DGV
1	p33	2	2	Loss	FAF1	31	I	No
1	p32.2	2	2	Gain	C1orf168	50.2	E/I	No
2	p23.2	2	2	Gain	ALK	62	E/I	Yes
2	q21.2–q21.3	2	2	Gain	MGAT5	72	E/I	No
3	p24.2	2	2	Gain	THRB	55.7	I	No
3	q11.2	2	3	Gain	LOC255025	50	E/I	No
3	q12.2	2	3	Gain	ABI3BP	143	E/I	Yes
3	q13.13	2	3	Gain	DZIP3	10.6	I	No
3	q13.31	2	3	Gain	ZBTB20	39	I	No
3	q13.31	2	3	Gain	GAP43	399	T	No
3	q13.31	2	3	Gain	LSAMP	53	I	No
3	q13.33	2	3	Gain	TMEM39A	176	T	No
3	q13.33	2	3	Gain	KTELC1	176	T	No
3	q13.33	2	3	Gain	C3orf1	176	T	No
3	q13.33	2	3	Gain	CD80	176	T	No
3	q13.33	2	3	Gain	ADPRH	176	T	No
3	q21.1	2	3	Gain	HSPBAP1	101	E/I	No
3	q21.1	2	4	Gain	DIRC2	101	T	No
3	q21.1	2	4	Gain	LOC100129550	101	T	Yes
3	q21.1	2	4	Gain	SEC22A	114	T	No
3	q21.1	2	4	Gain	PTPLB	125	T	No
3	q21.1	3	4	Gain	MYLK	70	E/I	No
3	q21.1	2	4	Gain	CCDC14	121	E/I	Yes
3	q21.2	2	4	Gain	KALRN	169	T	No
3	q21.2	2	4	Gain	UMPS	169	T	No
3	q21.2	2	4	Gain	ZNF148	164	E/I	Yes
3	q21.2	2	4	Gain	ALDH1L1	171	E/I	No
3	q21.3	3	4	Gain	TXNRD3IT1	299	E/I	No
3	q21.3	3	4	Gain	CHCHD6	299	E/I	No
3	q21.3	2	4	Gain	KLHDC6	95	T	No
3	q21.3	2	4	Gain	RUVBL1	211	E/I	Yes
3	q21.3	2	4	Gain	EEFSEC	211	E/I	Yes
3	q21.3	2	4	Gain	GATA2	76	E/I	Yes
3	q21.3	3	4	Gain	LOC90246	76	T	Yes
3	q21.3	2	4	Gain	C3orf27	120.7	T	Yes
3	q21.3	2	4	Gain	TMCC1	268	T	No
3	q21.3	2	4	Gain	COL6A4P2	131	T	Yes
3	q22.1	2	4	Gain	MRPL3	62	E/I	Yes
3	q22.1	2	4	Gain	SNORA58	62	T	Yes
3	q22.1	3	5	Gain	CPNE4	46	I	Yes
3	q22.1	2	4	Gain	CPNE4	155	E/I	Yes
3	q22.1	2	4	Gain	TMEM108	120	I	Yes
3	q22.1	2	4	Gain	TOPBP1	69	E/I	No
3	q22.1	2	4	Gain	RYK	225	T	No
3	q22.1	2	4	Gain	ANAPC13	197	T	Yes
3	q22.1	2	4	Gain	CEP63	197	T	Yes
3	q22.2	2	4	Gain	EPHB1	144	E/I	No
3	q22.2	2	4	Gain	PPP2R3A	85	E/I	No
3	q22.3	2	4	Gain	SOX14	925	T	No
3	q22.3	3	4	Gain	CLDN18	121	T	Yes
3	q22.3	2	4	Gain	ARMC8	77	E/I	Yes
3	q22.3	2	4	Gain	TXNDC6	77	E/I	Yes
3	q22.3	2	4	Gain	ESYT3	202.7	E/I	No
3	q22.3	2	4	Gain	CEP70	202.7	T	No
3	q22.3	2	4	Gain	FAIM	202.7	T	No
3	q22.3	2	4	Gain	PIK3CB	202.7	E/I	No
3	q22.3	3	4	Gain	LOC729627	193	T	No
3	q22.3	3	4	Gain	LOC389151	193	T	No
3	q22.3	3	4	Gain	FLJ46210	193	T	No
3	q22.3	3	4	Gain	BPESC1	193	T	No
3	q22.3	2	4	Gain	PISRT1	319	T	No
3	q23	2	4	Gain	MRPS22	89	E/I	No
3	q23	2	4	Gain	COPB2	89	T	No
3	q23	3	4	Gain	NMNAT3	277.8	E/I	No
3	q23	4	5	Gain	CLSTN2	46	I	Yes
3	q23	2	4	Gain	TRIM42	443	T	Yes
3	q23	2	4	Gain	SLC25A36	443	T	Yes
3	q24	2	4	Gain	SLC9A9	138	E/I	Yes
3	q24	2	4	Gain	PLSCR4	47	E/I	No
3	q24	2	4	Gain	PLSCR5	69	T	No
3	q24	2	4	Gain	AGTR1	194	E/I	No
3	q25.1	2	4	Gain	P2RY13	74	E/I	No
3	q25.1	2	4	Gain	MED12L	74	E/I	No
3	q25.1	2	4	Gain	P2RY13	74	T	No
3	q25.2	2	4	Gain	SGEF	364	E/I	Yes
3	q25.2–q25.31	3	4	Gain	MME	87.4	E/I	No
3	q25.32	2	4	Gain	VEPH1	78	E/I	Yes
3	q25.32	2	4	Gain	C3orf55	78	E/I	No
3	q25.32	3	4	Gain	MLF1	50	E/I	No
3	q26.1	2	4	Gain	C3orf57	120.6	E/I	No
3	q26.1	2	4	Gain	OTOL1	120.6	T	No
3	q26.1	3	4	Gain	SI	747	T	No
3	q26.1	3	4	Gain	BCHE	329	E/I	No
3	q26.1	2	4	Gain	ZBBX	307	T	No
3	q26.2	6	7	Gain	MDS1	28	E/I	No
3	q26.2	2	4	Gain	TERC	59	T	Yes
3	q26.2	2	4	Gain	ARPM1	59	T	Yes
3	q26.2	2	4	Gain	MYNN	59	T	Yes
3	q26.2	2	4	Gain	LRRC34	59	E/I	Yes
3	q26.2	3	5	Gain	TNIK	31	E/I	No
3	q26.31	2	4	Gain	NLGN1	125	I	Yes
3	q26.31	2	4	Gain	NLGN1	64	E/I	No
3	q26.31	2	4	Gain	NAALADL2	113	E/I	Yes
3	q26.32	2	4	Gain	TBL1XR1	60	E/I	No
3	q26.32	2	4	Gain	KCNMB2	121	E/I	No
3	q26.33	2	4	Gain	USP13	59	E/I	No
3	q26.33	2	4	Gain	PEX5L	81	E/I	No
3	q26.33	2	4	Gain	CCDC39	118	E/I	Yes
3	q27.1	2	4	Gain	YEATS2	112	E/I	No
3	q27.1	2	4	Gain	MAP6D1	112	T	No
3	q27.1	2	4	Gain	PARL	112	E/I	No
3	q27.2	2	4	Gain	VPS8	218	E/I	No
3	q27.2	2	4	Gain	ETV5	157	T	No
3	q27.2	2	4	Gain	DGKG	157	E/I	No
3	q27.3	2	4	Gain	CRYGS	110	E/I	No
3	q27.3	2	4	Gain	TBCCD1	110	T	No
3	q27.3	2	4	Gain	DNAJB11	110	T	No
3	q27.3	2	4	Gain	AHSG	110	T	Yes
3	q27.3	2	4	Gain	FETUB	110	E/I	Yes
3	q27.3	2	4	Gain	ST6GAL1	46	E/I	Yes
3	q27.3	2	4	Gain	MASP1	428	E/I	No
3	q27.3	3	4	Gain	RTP4	148	T	No
3	q27.3	2	4	Gain	SST	428	T	No
3	q27.3	2	4	Gain	FLJ42393	191	T	Yes
3	q28	3	4	Gain	LPP	191	E/I	Yes
3	q28	2	4	Gain	TP63	142	E/I	No
3	q28	2	4	Gain	CLDN1	203	T	No
3	q28	2	4	Gain	CLDN16	203	T	No
3	q28	2	4	Gain	TMEM207	203	T	No
3	q29	2	4	Gain	C3orf59	396	E/I	No
3	q29	2	4	Gain	MGC2889	396	T	Yes
3	q29	2	4	Gain	HRASLS	396	T	Yes
3	q29	2	4	Gain	ATP13A5	396	E/I	No
3	q29	2	4	Gain	ATP13A4	158	E/I	Yes
3	q29	2	4	Gain	OPA1	158	T	Yes
3	q29	2	4	Gain	GP5	97	E/I	No
3	q29	2	4	Gain	ATP13A3	97	T	Yes
3	q29	2	4	Gain	TM4SF19	87	E/I	Yes
3	q29	2	4	Gain	UBXN7	87	E/I	Yes
3	q29	2	4	Gain	DLG1	240	E/I	Yes
3	q29	2	4	Gain	FYTTD1	50	T	Yes
3	q29	2	4	Gain	LRCH3	50	E/I	Yes
3	q29	2	4	Gain	RPL35A	91	E/I	Yes
3	q29	2	4	Gain	IQCG	91	E/I	Yes
3	q29	2	4	Gain	LMLN	91	T	Yes
4	q13.3	2	2	Gain	SLC4A4	46	E/I	No
11	p15.1	2	2	Gain	NELL1	43	I	No
14	q13.1	2	2	Gain	NPAS3	43	I	Yes
16	p11.1	2	2	Gain	LOC283914	277	T	Yes
21	p11.2–p11.1	2	3	Loss	TPTE	107	T	Yes
X	p22.33	3	3	Gain	DHRSX	31	E/I	Yes
X	q12	2	2	Gain	EDA2R	91	E/I	Yes
Y	q11.21	2	2	Gain	USP9Y	60	E/I	No

129 gains concerned the long arm of chromosome 3 (3q). 123 gains concerned gene coding regions. 75 CNA did not include previously reported polymorphism (Database of Genomic Variants, DGV). Gain of one exon of MDS1 (part of MECOM gene) was recurrently observed in 7 patients (including mosaicism phenomenon)
Chr chromosome, Recurrence number of patients with the same CNA, CN state Copy Number state, gain or loss

Back to article page

ISSN: 1756-0500

Contact us

Submission enquiries: bmcresearchnotes@biomedcentral.com
General enquiries: ORSupport@springernature.com